Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
Crossref DOI link: https://doi.org/10.1007/s40744-019-00191-6
Published Online: 2020-01-06
Published Print: 2020-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Best, Jennie H.
Vlad, Steven C.
Pei, Jinglan
Funding for this research was provided by:
Genentech
Text and Data Mining valid from 2020-01-06
Version of Record valid from 2020-01-06
Article History
Received: 7 November 2019
First Online: 6 January 2020